• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Sun, 26.07.26

Search results


December 2024
Moti Ravid MD FACP, Zvi Ackerman MD, Samuel N. Heyman MD, George M. Weisz MD FRACS BA MA

Letter 1: "Not type 2" by Moti Ravid 

Letter 2: "Hyponatremia, hyperkalemia, and acute kidney injury: clues for the diagnosis of uroperitoneum in patients with new-onset ascites" by Zvi Ackerman and Samuel N. Heyman, 

Letter 3: "Surgery in Mauthausen Concentration Camp" by George M. Weisz

October 2023
Samuel N. Heyman MD, Yuri Gorelik MD, Mogher Khamaisi MD PhD, Zaid Abassi PhD

Recent studies using propensity score matching have clearly indicated that contrast nephropathy following computed tomography occurs in hospitalized patients with advanced chronic kidney disease (eGFR < 30 ml/min/1.73 m2) and that this iatrogenic complication is likely underestimated because of concomitant renal functional recovery, unrelated to the imaging procedure. These findings should be considered regarding contrast-enhanced studies in such patients.

January 2021
Ariel Rokach MD MHA, Sarit Hochberg-Klein MD, Nissim Arish MD, Victoria Doviner MD, Rachel Bar-Shalom MD, Yehonatan Turner MD, Norman Heching MD, and Samuel N. Heyman MD
August 2018
Amichai Perlman MD, Samuel N Heyman MD, Joshua Stokar MD, David Darmon MD, Mordechai Muszkat MD and Auryan Szalat MD

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) (such as canagliflozin, empagliflozin, and dapagliflozin) are widely used to treat patients with type 2 diabetes mellitus (T2DM) to improve glycemic, cardiovascular and renal outcomes. However, based on post-marketing data, a warning label was added regarding possible occurrence of acute kidney injury (AKI).

Objectives: To describe the clinical presentation of T2DM patients treated with SGLT2i who were evaluated for AKI at our institution and to discuss the potential pathophysiologic mechanisms.

Methods: A retrospective study of a computerized database was conducted of patients with T2DM who were hospitalized or evaluated for AKI while receiving SGLT2i, including descriptions of clinical and laboratory characteristics, at our institution.

Results: We identified seven patients in whom AKI occurred 7–365 days after initiation of SGLT2i. In all cases, renin-angiotensin-aldosterone system blockers had also been prescribed. In five patients, another concomitant nephrotoxic agent (injection of contrast-product, use of nonsteroidal anti-inflammatory drugs or cox-2 inhibitors) or occurrence of an acute medical event potentially associated with AKI (diarrhea, sepsis) was identified. In two patients, only the initiation of SGLT2i was evident. The mechanisms by which AKI occurs under SGLT2i are discussed with regard to the associated potential triggers: altered trans-glomerular filtration or, alternatively, kidney medullary hypoxia.

Conclusions: SGLT2i are usually safe and provide multiple benefits for patients with T2DM. However, during particular medical circumstances, and in association with usual co-medications, particularly if baseline glomerular filtration rate is decreased, patients treated with SGLT2i may be at risk of AKI, thus warranting caution when prescribed.

October 2016
Naseem Shadafny MD, Samuel N. Heyman MD, Michael Bursztyn MD, Anna Dinaburg MD, Ran Nir-Paz MD and Zvi Ackerman MD
November 2015
Moshe Simons MD, Samuel N. Heyman MD, Michael Bursztyn MD, Oded Shalev MD, Nurith Hiller MD and Sarah Israel MD
June 2014
Hagit Peleg MD, Benjamin Koslowski MD, Nurit Hiller MD and Samuel N. Heyman MD
December 1999
Sophia Zlatkin MD, Suhail Aamar MD, MSc, Galia Specter MD, David Leibowitz MD, Natalia Simanovsky MD, Dror Yeshurun MD and Samuel N Heyman MD
 Background: Takayasu's arteritis is a rare, probably underdiagnosed disorder in Israel.

Objective: To evaluate the contribution of computerized tomography to the diagnosis of Takayasu's arteritis.

Methods: A retrospective analysis of the diagnostic process was recently conducted in three consecutive patients diagnosed over the last 3 years.

Results: Three females of Arab origin with Takayasu's arteritis were recently identified by CT. In two of the three patients the imaging procedure was performed for different working hypotheses, and the radiological findings (wall thickening, perivascular edema, and segmental intraluminal obliteration of the aorta and its major branches) were unexpected. In these two patients, repeated physical examination following the imaging procedure disclosed initially missed findings that could have led to an earlier consideration of Takayasu's arteritis (bruits above the epigastrium, subclavian and carotid arteries, and absent brachial pulses). Retrospective analysis of the patients' symptoms following CT revealed the true nature of the patients' misinterpreted complaints (e.g., typical abdominal angina replaced a faulty obtained history compatible with renal colic or dyspepsia). In the third patient CT was performed for the evaluation of an epigastric bruit associated with constitutional complaints. The diagnosis of aortitis, based upon the presence of diffuse aortic wall thickening and edema of the surrounding fat, without intraluminal narrowing, could have been missed by angiography, the traditional "gold standard" diagnostic procedure. All three patients complained of ill-defined epigastric abdominal pain and had epigastric tenderness during examination.

Conclusions: CT has the potential for detecting Takayasu's disease and may be superior to angiography, particularly at the early non-obliterative stage. Since the diagnosis of Takayasu's disease is rarely considered, the expanding use of CT and MRI technologies may reveal missed cases that are evaluated for other plausible diagnoses. The true incidence of Takayasu's arteritis in Israel may be much higher than reported, particularly in the Arab population. Our findings suggest that epigastric tenderness, originating from active inflammatory reaction in the abdominal aortic wall, should be considered as a diagnostic criterion of Takayasu's aortitis.

Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel